Raymond James & Associates Alnylam Pharmaceuticals, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

A detailed history of Raymond James & Associates transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 10,942 shares of ALNY stock, worth $2.63 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,942

Previous 16,257 32.69%

Holding current value

$2.63 Million

Previous $3.95 Million 23.82%

% of portfolio

0.0%

Previous 0.0%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$233.81 - $287.01 $1.24 Million - $1.53 Million	-5,315 Reduced 32.69%	10,942 $3.01 Million
Q2 2024 Jul 19, 2024	BUY	$143.31 - $247.0 $156,064 - $268,983	1,089 Added 7.18%	16,257 $3.95 Million
Q1 2024 Apr 22, 2024	BUY	$146.51 - $198.2 $129,221 - $174,812	882 Added 6.17%	15,168 $2.27 Million
Q4 2023 Jan 16, 2024	BUY	$151.41 - $196.57 $283,893 - $368,568	1,875 Added 15.11%	14,286 $2.73 Million
Q3 2023 Oct 24, 2023	BUY	$170.77 - $211.65 $102,120 - $126,566	598 Added 5.06%	12,411 $2.2 Million
Q2 2023 Jul 25, 2023	BUY	$185.01 - $212.05 $227,562 - $260,821	1,230 Added 11.62%	11,813 $2.24 Million
Q1 2023 Apr 14, 2023	SELL	$182.66 - $235.53 $97,540 - $125,773	-534 Reduced 4.8%	10,583 $2.12 Million
Q4 2022 Feb 08, 2023	BUY	$185.53 - $241.31 $92,765 - $120,655	500 Added 4.71%	11,117 $2.64 Million
Q3 2022 Oct 25, 2022	SELL	$138.54 - $232.0 $765,294 - $1.28 Million	-5,524 Reduced 34.22%	10,617 $2.13 Million
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $2.04 Million - $2.86 Million	-16,919 Reduced 51.18%	16,141 $2.35 Million
Q1 2022 May 11, 2022	SELL	$127.18 - $173.91 $1.33 Million - $1.82 Million	-10,443 Reduced 24.01%	33,060 $5.4 Million
Q4 2021 Feb 08, 2022	BUY	$159.56 - $209.29 $606,647 - $795,720	3,802 Added 9.58%	43,503 $7.38 Million
Q3 2021 Nov 02, 2021	SELL	$169.75 - $207.73 $14,768 - $18,072	-87 Reduced 0.22%	39,701 $7.5 Million
Q2 2021 Aug 11, 2021	BUY	$128.63 - $176.89 $406,084 - $558,441	3,157 Added 8.62%	39,788 $6.75 Million
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $345,865 - $479,106	2,727 Added 8.04%	36,631 $5.17 Million
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $278,035 - $332,367	2,261 Added 7.15%	33,904 $4.41 Million
Q3 2020 Nov 04, 2020	BUY	$121.19 - $165.49 $123,371 - $168,468	1,018 Added 3.32%	31,643 $4.61 Million
Q2 2020 Jul 28, 2020	BUY	$104.21 - $156.44 $429,449 - $644,689	4,121 Added 15.55%	30,625 $4.54 Million
Q1 2020 Apr 21, 2020	BUY	$93.12 - $133.99 $2.29 Million - $3.29 Million	24,540 Added 1249.49%	26,504 $2.89 Million
Q4 2019 Feb 12, 2020	BUY	$74.51 - $124.23 $146,337 - $243,987	1,964 New	1,964 $226,000

Others Institutions Holding ALNY

# of Institutions

643

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.6B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Alnylam Pharmaceuticals, Inc. Transaction History